CR - Sunesis rises 1.9% after Viracta sees registration trial in H1 for lymphoma regimen

Sunesis Pharmaceuticals (SNSS) gains 1.9% in early trading after Viracta Therapeutics, the company Sunesis has agreed to acquire, reports complete responses were observed across multiple  EBV+ lymphoma subtypes in a Phase 2 trial investigating an oral regimen of nanatinostat and valganciclovir.Notes preliminary efficacy in Phase 2 is consistent with Phase 1b results.Results also suggest program was highly active in T/NK-NHL (n=10) with an overall response rate of 80% (8/10) and complete response rate (CR) of 40%.Based on the outcome of end of Phase 2 meeting with the U.S. Food and Drug Administration in November, Viracta plans to start a global registration trial in relapsed/refractory EBV+ lymphomas in H1 2021 in a trial that's designed to support multiple potential marketing approvals across the various subtypes of EBV+ lymphomas.An end of Phase 2 meeting with the FDA to address chemistry, manufacturing and controls is planned for December 2020, and preliminary comments from the agency indicate alignment in key areas."EBV+ lymphoma is an

For further details see:

Sunesis rises 1.9% after Viracta sees registration trial in H1 for lymphoma regimen